{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:32:35Z","timestamp":1792287155976,"version":"4.4.0"},"reference-count":27,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To compare the 12-month effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) in adults with insulin-treated type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This is a single-center, parallel, open-label, randomized controlled trial including adults with inadequately controlled, insulin-treated type 2 diabetes from the outpatient clinic at Steno Diabetes Center Copenhagen, Denmark. Inclusion criteria were \u226518 years of age, insulin-treated type 2 diabetes, and HbA1c \u22657.5% (58 mmol\/mol). Participants were randomly assigned (1:1) to 12 months of either CGM or BGM. All participants received a diabetes self-management education course and were followed by their usual health care providers. Primary outcome was between-group differences in change in time in range (TIR) 3.9\u201310.0 mmol\/L, assessed at baseline, after 6 and 12 months by blinded CGM. The prespecified secondary outcomes were differences in change in several other glycemic, metabolic, and participant-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The 76 participants had a median baseline HbA1c of 8.3 (7.8, 9.1)% (67 [62\u201376] mmol\/mol), and 61.8% were male. Compared with BGM, CGM usage was associated with significantly greater improvements in TIR (between-group difference 15.2%, 95% CI 4.6; 25.9), HbA1c (\u22120.9%, \u22121.4; \u22120.3 [\u22129.4 mmol\/mol, \u221215.2; \u22123.5]), total daily insulin dose (\u221210.6 units\/day, \u221219.9; \u22121.3), weight (\u22123.3 kg, \u22125.5; \u22121.1), and BMI (\u22121.1 kg\/m2, \u22121.8; \u22120.3) and greater self-rated diabetes-related health, well-being, satisfaction, and health behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In adults with inadequately controlled insulin-treated type 2 diabetes, the 12-month impact of CGM was superior to BGM in improving glucose control and other crucial health parameters. The findings support the use of CGM in the insulin-treated subgroup of type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-2194","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:03:41Z","timestamp":1710504221000},"page":"881-889","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":70,"title":["Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial"],"prefix":"10.2337","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-6868","authenticated-orcid":false,"given":"Nanna","family":"Lind","sequence":"first","affiliation":[{"name":"1Department of Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark"},{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-5427","authenticated-orcid":false,"given":"Merete B.","family":"Christensen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte L.","family":"Hansen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-8271","authenticated-orcid":false,"given":"Kirsten","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark"},{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2024041918514836000_B1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2024041918514836000_B2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","article-title":"Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis","volume":"137","author":"Khunti","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2024041918514836000_B3","doi-asserted-by":"crossref","first-page":"e2247656","DOI":"10.1001\/jamanetworkopen.2022.47656","article-title":"Trends and disparities in glycemic control and severe hyperglycemia among US adults with diabetes using insulin, 1988-2020","volume":"5","author":"Venkatraman","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024041918514836000_B4","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2024041918514836000_B5","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc23-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2024041918514836000_B6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"2024041918514836000_B7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2024041918514836000_B8","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.2021.6530","article-title":"Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes","volume":"325","author":"Karter","year":"2021","journal-title":"JAMA"},{"key":"2024041918514836000_B9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2337\/dc19-1459","article-title":"Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials","volume":"43","author":"Maiorino","year":"2020","journal-title":"Diabetes Care"},{"key":"2024041918514836000_B10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M16-2855","article-title":"Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial","volume":"167","author":"Beck","year":"2017","journal-title":"Ann Intern Med"},{"key":"2024041918514836000_B11","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"key":"2024041918514836000_B12","doi-asserted-by":"crossref","first-page":"e040648","DOI":"10.1136\/bmjopen-2020-040648","article-title":"Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial","volume":"11","author":"Lind","year":"2021","journal-title":"BMJ Open"},{"key":"2024041918514836000_B13","first-page":"EP329","article-title":"A new combined diabetes and CGM education program for adults with insulin-treated type 2 diabetes","volume":"24","author":"Lind","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2024041918514836000_B14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2024041918514836000_B15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: a systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother Psychosom"},{"key":"2024041918514836000_B16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/dme.12887","article-title":"How to assess diabetes distress: comparison of the problem areas in diabetes scale (paid) and the diabetes distress scale (DDS)","volume":"33","author":"Schmitt","year":"2016","journal-title":"Diabet Med"},{"key":"2024041918514836000_B17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/dme.13162","article-title":"An empirically derived short form of the Hypoglycaemia Fear Survey II","volume":"34","author":"Grabman","year":"2017","journal-title":"Diabet Med"},{"key":"2024041918514836000_B18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/dia.2014.0417","article-title":"Development of a new measure for assessing glucose monitoring device-related treatment satisfaction and quality of life","volume":"17","author":"Polonsky","year":"2015","journal-title":"Diabetes Technol Ther"},{"key":"2024041918514836000_B19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1464-5491.1994.tb00316.x","article-title":"Guidelines for encouraging psychological well-being: report of a working group of the World Health Organization Regional Office for Europe and International Diabetes Federation European region St Vincent Declaration Action Programme for Diabetes","volume":"11","author":"Bradley","year":"1994","journal-title":"Diabet Med"},{"key":"2024041918514836000_B20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1477-7525-5-57","article-title":"The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ","volume":"5","author":"Bradley","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"2024041918514836000_B21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/ijerph15050947","article-title":"Use of diabetes treatment satisfaction questionnaire in diabetes care: importance of patient-reported outcomes","volume":"15","author":"Saisho","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"2024041918514836000_B22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1403494815602830","article-title":"Categorical answer modes provide superior validity to open answers when asking for level of physical activity: a cross-sectional study","volume":"44","author":"Olsson","year":"2016","journal-title":"Scand J Public Health"},{"key":"2024041918514836000_B23","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.3390\/nu7075231","article-title":"The reliability and validity of the perceived dietary adherence questionnaire for people with type 2 diabetes","volume":"7","author":"Asaad","year":"2015","journal-title":"Nutrients"},{"key":"2024041918514836000_B24","author":"Ozenne"},{"key":"2024041918514836000_B25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"2024041918514836000_B26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1089\/dia.2022.0101","article-title":"Impact of missing data on the accuracy of glucose metrics from continuous glucose monitoring assessed over a 2-week period","volume":"25","author":"Smith","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"2024041918514836000_B27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s13300-022-01324-x","article-title":"Cost-effectiveness of a real-time continuous glucose monitoring system versus self-monitoring of blood glucose in people with type 2 diabetes on insulin therapy in the UK","volume":"13","author":"Isitt","year":"2022","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/doi\/10.2337\/dc23-2194\/757789\/dc232194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/doi\/10.2337\/dc23-2194\/757789\/dc232194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T14:52:58Z","timestamp":1713538378000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/5\/881\/154335\/Comparing-Continuous-Glucose-Monitoring-and-Blood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-2194","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}